Oncology and reproductive outcomes over 16 years of malignant ovarian germ cell tumors treated by fertility sparing surgery

Table 2 Progression cases (n = 4)

SN	Year	Age	Stage	Histology	Chemotherapy	Cycle	Site	Primary surgery	Note
50	2013	17	IC1	Immature teratoma grade 2	None	-	Right	Right SO and appendectomy	PFS 3 mos →pelvic recurrence → debulking tumor and BEP × 6 cycles → alive without disease DFS 103 mos, overall survival 109 mo
52	2013	15	IV	Yolk sac tumor	BEP	8	Right	Right SO and left cystectomy and omentectomy	Progression after BEP × 8: Liver & lung metastasis → TIP x 2 → PT × 1 → ifosfamide × 1 → progression → death (overall survival 16 mo)
74	2010	18	IV	Choriocarcinoma	EMACO	6	Left	Left SO and omentectomy and appendectomy and PAN sampling	EMACO × 6 → progression (PFS 7 mos) → cisplatin and ifosfamide × 5 → paclitaxel × 1 → Act D and 5 FU × 1 → VAC × 1 → TAH and right SO (19/4/2011) → EMA/EP × 9 → TP/TE × 1 → BEP × 2 → palliative treatment → death 5/7/2012 overall survival 28 mo
110	2005	16	IV	Yolk sac tumor	BEP × 2 → EP × 11	12	Right	Right SO and appendectomy	Progression after EP × 11 → ifosfamide × 1 → EMA × 1 → single paclitaxel × 1 → palliative RT 25/1/2006 → VAC × 1 → Death 4/7/2007,OS 30 mo (lung fibrosis after BEP × 2)

PFS: Progression-free survival; DFS: Disease-free survival; SO: Salpingo-oophorectomy; PAN: Para-aortic lymph node; BEP: Bleomycin etoposide cisplatin; EMACO: Etoposide methotrexate actinomycin D cyclophosphamide vincristine; TIP: Paclitaxel ifosfamide cisplatin; PT: Paclitaxel carboplatin; Act D; actinomycin d; EMA/EP: Etoposide methotrexate actinomycin D etoposide cisplatin; 5FU: Fluorouracil; VAC: Vincristine dactinomycin and cyclophosphamide; TP/TE: Paclitaxel cisplatin/paclitaxel etoposide; TAH: Total abdominal hysterectomy; EP: Etoposide cisplatin, palliative; RT: Radiotherapy.